FDA Approves Ide-Cel for Triple-Class Exposed R/R Multiple Myeloma
The FDA has approved ide-cel (Abecma) for adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy.
Source: onclive.com
Ide Cel News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Ide Cel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Ide Cel Today - Breaking & Trending Today
Immune Engager Therapies Demonstrate Promise Following Relapse on Ide-Cel in Multiple Myeloma
Treatment with immune engager therapies following relapse on ide-cel resulted in better median PFS vs other therapies for patients with multiple myeloma.
Source: onclive.com
Idecabtagene Vicleucel Approaches EU Approval in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
The EMA's CHMP has recommended the approval of idecabtagene vicleucel in patients with multiple myeloma who received at least 2 prior therapies.
Source: onclive.com
KarMMA-3: Trial of Ide-Cel in Patients with Triple Class Exposed R/R MM
Experts discuss the recent data presented at ASH 2023 from the KarMMA-3 trial in which ide-cel vs standard of care was studied in triple class exposed R/R MM patients.
Source: onclive.com
Ide-Cel Provides HRQOL Benefits Over Standard Regimens in R/R Multiple Myeloma
Idecabtagene vicleucel resulted in meaningful improvements in symptoms, functioning, overall health status, and health-related quality of life vs standard regimens in select patients with triple-class exposed relapsed/refractory multiple myeloma, according to updated data from the phase 3 KarMMa-3 trial.
Source: onclive.com